Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 300

Similar articles for PubMed (Select 17658067)

1.

[Monoclonal antibody therapy: a literature review].

Del Debbio CB, Tonon LM, Secoli SR.

Rev Gaucha Enferm. 2007 Mar;28(1):133-42. Review. Portuguese.

PMID:
17658067
2.

New solid tumor targets for therapeutic monoclonal antibodies.

Papkoff J.

Expert Opin Ther Targets. 2007 May;11(5):585-8.

PMID:
17465718
3.

CTLA-4 blockade: autoimmunity as treatment.

Kapadia D, Fong L.

J Clin Oncol. 2005 Dec 10;23(35):8926-8. Epub 2005 Oct 3. No abstract available.

4.

Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches.

Jurcic JG, Cathcart K, Pinilla-Ibarz J, Scheinberg DA.

Curr Opin Hematol. 2000 Jul;7(4):247-54. Review.

PMID:
10882181
5.

Antibody-based therapeutics in oncology.

Ross J, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A, Rolfe M.

Expert Rev Anticancer Ther. 2003 Feb;3(1):107-21. Review.

PMID:
12597355
6.

Improving the efficacy of antibody-based cancer therapies.

Carter P.

Nat Rev Cancer. 2001 Nov;1(2):118-29. Review.

PMID:
11905803
7.

[Principal therapeutic uses of monoclonal antibodies in oncology].

Penault-Llorca F, Etessami A, Bourhis J.

Cancer Radiother. 2002 Nov;6 Suppl 1:24s-28s. Review. French.

PMID:
12587379
8.

[Monoclonal antibodies and cancer].

López González JS, Selman Lama M.

Salud Publica Mex. 1985 May-Jun;27(3):213-34. Review. Spanish. No abstract available.

PMID:
2996157
9.

Antibody-directed therapies for hematological malignancies.

Linenberger ML, Maloney DG, Bernstein ID.

Trends Mol Med. 2002 Feb;8(2):69-76. Review.

PMID:
11815272
10.

Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.

Ferrini S, Sforzini S, Canevari S.

Methods Mol Biol. 2001;166:177-92. Review. No abstract available.

PMID:
11217367
11.

Antibody-based immunotherapy in high-risk neuroblastoma.

Johnson E, Dean SM, Sondel PM.

Expert Rev Mol Med. 2007 Dec 17;9(34):1-21. Review.

PMID:
18081947
12.

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.

Wels W, Groner B, Hynes NE.

Curr Top Microbiol Immunol. 1996;213 ( Pt 3):113-28. Review. No abstract available.

PMID:
8815001
13.

Tumor-directed targeting of liposomes.

Park YS.

Biosci Rep. 2002 Apr;22(2):267-81. Review.

PMID:
12428904
14.

Monoclonal antibody therapy for cancer.

Lovett DR, Scheinberg DA, Houghton AN.

Cancer Chemother Biol Response Modif. 1991;12:147-63. Review. No abstract available.

PMID:
1931442
15.

[Monoclonal antibodies in the treatment of hematological malignancies].

Itälä M.

Duodecim. 2002;118(16):1647-56. Review. Finnish. No abstract available.

PMID:
12271942
16.

The use of monoclonal antibody immunoconjugates in cancer therapy.

Pietersz GA, Krauer K, McKenzie IF.

Adv Exp Med Biol. 1994;353:169-79. Review. No abstract available.

PMID:
7985535
17.

Technology evaluation: edrecolomab, Centocor Inc.

Abicht A, Lochmüller H.

Curr Opin Mol Ther. 2000 Oct;2(5):593-600. Review.

PMID:
11249762
18.

Monoclonal antibody therapy.

O'Mahony D, Bishop MR.

Front Biosci. 2006 May 1;11:1620-35. Review.

PMID:
16368542
19.

Biological impediments to monoclonal antibody-based cancer immunotherapy.

Christiansen J, Rajasekaran AK.

Mol Cancer Ther. 2004 Nov;3(11):1493-501. Review.

20.

Monoclonal antibodies as therapeutics in oncology.

Trikha M, Yan L, Nakada MT.

Curr Opin Biotechnol. 2002 Dec;13(6):609-14. Review.

PMID:
12482522
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk